Is Mesoblast (ASX:MSB) Trading Above its 52-Week Low?

Sonal Goyal

13 July 2026 12:20 AM AEST

Is Mesoblast (ASX:MSB) Trading Above its 52-Week Low?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast shares gained 4.910% during the latest ASX trading session.
The stock traded between AUD 2.280 and AUD 2.450 intraday.
Mesoblast's market capitalisation stood at AUD 2.89 billion.

Mesoblast Limited (ASX:MSB) traded higher during the latest session, with the stock rising 4.910% to AUD 2.350. The gain came after the stock closed at AUD 2.240 in the previous session.

During trading, the shares moved within an intraday range of AUD 2.280 to AUD 2.450. The bid and offer were quoted at AUD 2.330 and AUD 2.370, respectively, while the company remained listed as currently trading.

Trading Activity Exceeds Average Volume

Trading activity was above the stock's average daily turnover during the latest session. A total of 5,388,829 shares changed hands, exceeding the average trading volume of 3,417,798 shares.

Higher trading volume often reflects increased market participation during a session, although it does not indicate the direction of future share price movements.

Market Capitalisation and Share Information

Mesoblast has a market capitalisation of AUD 2.89 billion and is classified under the Pharmaceuticals, Biotechnology & Life Sciences industry group on the Australian Securities Exchange.

The company has been listed on the ASX since 16 December 2004. It has 1,294,612,776 ordinary fully paid shares on issue and carries the ISIN AU000000MSB8. Its foreign exempt status is listed as "No."

Stock Trades Within Broad 52-Week Range

Based on the latest available market data, Mesoblast shares have traded between AUD 1.630 and AUD 3.310 over the past 52 weeks.

At the latest traded price of AUD 2.350, the stock remains above its 52-week low and below its 52-week high. The 52-week range provides a reference for understanding the stock's historical price movement over the past year.

Snapshot of the Latest Trading Session

The latest trading session reflected positive price movement alongside elevated trading activity. The stock opened the session above its previous close and traded within a range of AUD 2.280 to AUD 2.450 before reaching AUD 2.350 at the latest quoted price.

Investors typically monitor metrics such as trading volume, market capitalisation, daily price range, and historical trading range alongside company announcements and financial disclosures when assessing listed companies.

Key Risks

Biotechnology stocks may experience significant share price volatility.
Clinical and regulatory developments can influence market sentiment.
Higher trading volumes may increase short-term price fluctuations.
Market conditions can affect healthcare sector valuations.

Summary

Mesoblast Limited (ASX: MSB) gained 4.910% during the latest trading session to AUD 2.350 from the previous close of AUD 2.240. The shares traded between AUD 2.280 and AUD 2.450, while trading volume reached 5.39 million shares, exceeding the average daily volume. The company has a market capitalisation of AUD 2.89 billion and 1.29 billion shares on issue.

FAQs

Q: What was Mesoblast's latest share price?

A:Mesoblast shares traded at AUD 2.350, representing a 4.910% increase during the latest ASX trading session.

Q: How many Mesoblast shares were traded today?

A:Approximately 5.39 million Mesoblast shares changed hands, exceeding the stock's average daily trading volume.

Q: What is Mesoblast's market capitalisation?

A:Mesoblast had a market capitalisation of approximately AUD 2.89 billion based on the latest available trading data.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.